{
    "General": {
        "Code": "87S",
        "Type": "Common Stock",
        "Name": "ROIVANT SCIENCES",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "BMG762791017",
        "LEI": null,
        "PrimaryTicker": "MAAC.US",
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "March",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Biotechnology",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Biotechnology",
        "GicSubIndustry": "Biotechnology",
        "Description": "Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 904,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 8627435520,
        "MarketCapitalizationMln": 8627.4355,
        "EBITDA": -1037155008,
        "PERatio": null,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 1.187,
        "DividendShare": 0,
        "DividendYield": 0,
        "EarningsShare": -1.36,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2023-06-30",
        "ProfitMargin": 0,
        "OperatingMarginTTM": -13.4781,
        "ReturnOnAssetsTTM": -0.2795,
        "ReturnOnEquityTTM": -0.7738,
        "RevenueTTM": 78585000,
        "RevenuePerShareTTM": 0.108,
        "QuarterlyRevenueGrowthYOY": 4.007,
        "GrossProfitTTM": -477063000,
        "DilutedEpsTTM": -1.36,
        "QuarterlyEarningsGrowthYOY": 0
    },
    "Valuation": {
        "TrailingPE": 0,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": 7083611648,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 771742016,
        "SharesFloat": 252876766,
        "PercentInsiders": 34.481,
        "PercentInstitutions": 58.518,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 1.2755,
        "52WeekHigh": 12.2,
        "52WeekLow": 2.915,
        "50DayMA": 9.594,
        "200DayMA": 7.7521,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0,
        "ForwardAnnualDividendYield": 0,
        "PayoutRatio": 0,
        "DividendDate": null,
        "ExDividendDate": null,
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {}
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}